# A Phase I Study of CFT8919 in Patients With Advanced NSCLC

> **NCT06641609** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 166 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer With EGFR Mutation

## Interventions

- **DRUG:** Dose-Escalation (Phase Ia) CFT8919 capsule
- **DRUG:** Dose-Expansion (Phase Ib) CFT8919 capsule
- **DRUG:** Cohort-Expansion (Phase Ic) CFT8919 capsule

## Key facts

- **NCT ID:** NCT06641609
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-13
- **Primary completion:** 2025-12-09
- **Final completion:** 2026-04-03
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06641609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06641609, "A Phase I Study of CFT8919 in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06641609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*